To characterize whether the ability of pharmacological FASN blockade to impede the tamoxifen-enhanced tumorigenicity of ER+/HER2+ breast cancer cells involved a differential regulation of ERα expression, we evaluated the effects of FASN inhibition on the status of ERα by immunoblotting. The gene discussed is FASN; the disease is breast carcinoma.